|
| 37389780 | A Mixed-Methods Approach for Evaluating Implementation Processes and Program Costs for a Hypertension Management Program Implemented in a Federally Qualified Health Center. | Prev Sci | 2024 |
| 36928318 | Prevalence of Eye and Vision Disorders in the Military Health System, Fiscal Year 2018. | Mil Med | 2023 |
| 37022712 | Association Between Social Determinants of Health and Examination-Based Vision Loss vs Self-reported Vision Measures. | JAMA Ophthalmol | 2023 |
| 37318810 | Prevalence of Diabetic Retinopathy in the US in 2021. | JAMA Ophthalmol | 2023 |
| 37140901 | Validity of Administrative Claims and Electronic Health Registry Data From a Single Practice for Eye Health Surveillance. | JAMA Ophthalmol | 2023 |
| 36881468 | Comparing Telephone Survey Responses to Best-Corrected Visual Acuity to Estimate the Accuracy of Identifying Vision Loss: Validation Study. | JMIR Public Health Surveill | 2023 |
| 36637915 | Trends in the Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Commercially Insured Adults Aged <65 Years. | Diabetes Care | 2023 |
| 34560128 | The Economic Burden of Vision Loss and Blindness in the United States. | Ophthalmology | 2022 |
| 35797011 | County-Level Variation in the Prevalence of Visual Acuity Loss or Blindness in the US. | JAMA Ophthalmol | 2022 |
| 36326752 | Prevalence of Age-Related Macular Degeneration in the US in 2019. | JAMA Ophthalmol | 2022 |
| 35238912 | Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries. | JAMA Ophthalmol | 2022 |
| 32663529 | Vision Impairment and Blindness Prevalence in the United States: Variability of Vision Health Responses across Multiple National Surveys. | Ophthalmology | 2021 |
| 34530688 | The Prevalence of Diagnosis of Major Eye Diseases and their Associated Payments in the Medicare Fee-for-Service Program. | Ophthalmic Epidemiol | 2021 |
| 33983373 | Prevalence of Visual Acuity Loss or Blindness in the US: A Bayesian Meta-analysis. | JAMA Ophthalmol | 2021 |
| 31725705 | Disparities in Receipt of Eye Exams Among Medicare Part B Fee-for-Service Beneficiaries with Diabetes - United States, 2017. | MMWR Morb Mortal Wkly Rep | 2019 |
| 29566863 | Establishing a Vision and Eye Health Surveillance System for the Nation: A Status Update on the Vision and Eye Health Surveillance System. | Ophthalmology | 2018 |
| 28796854 | The Promise and Potential of Pediatric Vision Data. | JAMA Ophthalmol | 2017 |
| 28358948 | Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. | JAMA Ophthalmol | 2017 |
| 29404448 | Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations. | Hepatol Commun | 2017 |
| 26707033 | The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics. | Hepatology | 2016 |
| 27490785 | Public Attitudes About Eye and Vision Health. | JAMA Ophthalmol | 2016 |
| 25778747 | The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. | Clin Infect Dis | 2015 |
| 22933435 | Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. | Diabetes Care | 2013 |
| 23631946 | The economic burden of vision loss and eye disorders among the United States population younger than 40 years. | Ophthalmology | 2013 |
| 21877675 | The potential cost-effectiveness of amblyopia screening programs. | J Pediatr Ophthalmol Strabismus | 2012 |
| 23754160 | The economics of the initial preventive physical examination in medicare-reply. | Arch Ophthalmol | 2012 |
| 23204444 | Cost-effectiveness of screening for microalbuminuria among African Americans. | J Am Soc Nephrol | 2012 |
| 22307760 | Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. | Swiss Med Wkly | 2012 |
| 22232367 | The cost-effectiveness of Welcome to Medicare visual acuity screening and a possible alternative welcome to medicare eye evaluation among persons without diagnosed diabetes mellitus. | Arch Ophthalmol | 2012 |
| 22056542 | The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. | Ann Intern Med | 2012 |
| 22121109 | The global burden of hepatitis E virus genotypes 1 and 2 in 2005. | Hepatology | 2012 |
| 20739252 | Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. | Dig Liver Dis | 2011 |
| 22005629 | A cost-benefit analysis of lipid standardization in the United States. | Prev Chronic Dis | 2011 |
| 21492158 | The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy. | Health Serv Res | 2011 |
| 21076360 | Cost-effectiveness of glaucoma interventions in Barbados and Ghana. | Optom Vis Sci | 2011 |
| 20116910 | A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. | Am J Kidney Dis | 2010 |
| 20116911 | A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. | Am J Kidney Dis | 2010 |
| 19285730 | The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. | Ophthalmology | 2009 |
| 19365036 | Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. | Arch Ophthalmol | 2009 |
| 17462738 | Technical appendix: cost-effectiveness of vitamin therapy for age-related macular degeneration. | Ophthalmology | 2007 |
| 17320962 | Cost-effectiveness of vitamin therapy for age-related macular degeneration. | Ophthalmology | 2007 |
| 16525173 | Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. | Med Decis Making | 2006 |
| 15257854 | Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN. | J Womens Health (Larchmt) | 2004 |